Latest News & Stories
Sabin Completes Enrollment in All Phase 2 Clinical Trials for cAd3-Marburg Vaccine and cAd3-Sudan Ebolavirus Vaccine
Phase 2 clinical trials to evaluate the safety and immunogenicity of the two monovalent vaccines, both on the cAd3 platform, began in healthy volunteers in Africa in 2023 and in the United States in 2025. The African trials, with sites in Kenya and Uganda, completed participant follow-up last year and reporting activities are progressing.
Six in One: How Sabin is Supporting Hexavalent Vaccine Adoption
The hexavalent vaccine protects against six diseases in a one shot — improving efficiency, cutting costs, and saving lives. Sabin and partners are generating timely evidence and fostering collaboration to support smooth adoption.
Global Immunization Insights Dashboard
Sabin's dashboard provides a broader view of the factors impacting immunization in order to better understand what is needed to reach 1 billion children with vaccines by the end of the decade.
From Research to Action: Solving Real World Health Problems
Sabin’s Applied Epidemiology team turns real‑world data into vaccine action—partnering with local researchers to track disease burden, study vaccine safety and effectiveness, and figure out where vaccines are most needed and how best to use them. We generate practical evidence and share results so decision‑makers can act fast and improve how vaccines are used to prevent disease.
Local Impact, Global Change
Explore how Sabin’s partners drive impact on the ground. Discover their stories here, and check back for updates on new locations and projects.
Making a Case for Vaccines
News & Resources
We make vaccines more accessible, enable innovation and expand immunization across the globe.